Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Puma Biotechnology
(NQ:
PBYI
)
2.650
+0.130 (+5.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Puma Biotechnology
< Previous
1
2
3
4
Next >
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Second Quarter Financial Results
August 01, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
July 18, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
June 03, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
June 02, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Join Russell 3000 Index
May 28, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
May 23, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports First Quarter Financial Results
May 02, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
April 18, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
March 20, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
February 29, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 27, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
February 22, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
February 13, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
3 small-cap biotechs with potential breakthroughs in 2024
February 06, 2024
These small-cap biotech stocks feature large addressable markets combined with positive analyst sentiment and potential breakthroughs in 2024.
Via
MarketBeat
Topics
Bankruptcy
Exposures
Financial
Legal
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
January 11, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
December 11, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
November 06, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Third Quarter 2023 Financial Results
November 02, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
October 19, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
October 14, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
September 21, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
August 08, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.